Sorbonne Université, GHU Pitié-Salpêtrière Hospital
Paris, France
Country
France
Institution
Head of the muscle pathology functional unit at Institut de Myologie, Laboratoire de Neuropathologie,Hôpital De La Pitié-Salpêtrière
Coordinator of the ERN-EURO-NMD
Education summary
• Subspecialty in Neuropathology, Hospital Geral de Santo Antonio, Porto, 1996 ‐ 1998
• Specialist in Neurology, General Medical Council in Portugal, 1995
• “Fellowship”, neuromuscular pathology, Unit 153‐INSERM, PARIS, France, 1993
• Degree in Medicine, Faculty of Medicine, Classical University of Lisbon, 1981 ‐1987
Career summary
Coordinator of the ERN EURO-NMD since 2018 and co-coordinator from 2016 to 2017.
Board certified neurologist and neuropathologist with long standing clinical and research expertise in neuromuscular disorders. Expertise on rare diseases policies.
2022-present - APHP, Paris, France - Head of the neuromuscular pathology unit
2018 - 2022 - Neuromuscular pathology unit, Association de l'institut de myologie (AIM), Paris, France - Researcher
2012 -2018 - lnstitut of Genetic Medicine (John Walton Muscular Dystrophy Research Centre), Newcastle University, UK
2004 - 2012 - Neuromuscular Unit of the Institute of Molecular Medicine, Faculty of Medicine, University of Lisbon, Portugal
2004 - 2012 - Santa Maria Hospital, Lisbon, Portugal - Co-head of the neurology day hospital
1998 - 2012 - Santa Maria Hospital, Lisbon, Portugal - Head of neuromuscular pathology laboratory
What is the personal or professional achievement you’re most proud of?
Two key achievements stand out in my professional journey.
The first was successfully coordinating a network of over 80 expert centres across Europe under the umbrella of the European Reference Network for Rare Neuromuscular Diseases (ERN EURO-NMD), fostering collaboration and harmonisation of care standards.
The second was being elected by peers to serve on the current Executive Board of the World Muscle Society (WMS), reflecting recognition of my contributions and leadership within the international neuromuscular community.
Why did you first join the WMS?
I first joined the World Muscle Society (WMS) because it was the leading platform to deepen my knowledge in neuromuscular diseases and to connect with peers whose work was driving meaningful advances in the field. It offered not only cutting-edge scientific content but also a unique environment to build collaborative networks that could help shape the future of care and research in NMDs.
What is your goal in joining the Executive Board?
My goal in joining the Executive Board of the WMS is to actively contribute to the Society’s mission by supporting its initiatives and bringing my experience to benefit the wider neuromuscular community. I aim to foster collaboration, promote knowledge sharing, and help advance the quality of care and research in our field.
